Podocyte number and density changes during early human life

Masao Kikuchi¹,² · Larysa Wickman³ · Raja Rabah⁴ · Roger C. Wiggins¹

Abstract
Background Podocyte depletion, which drives progressive glomerulosclerosis in glomerular diseases, is caused by a reduction in podocyte number, size or function in the context of increasing glomerular volume.

Methods Kidneys obtained at autopsy from premature and mature infants who died in the first year of life (n = 24) were used to measure podometric parameters for comparison with previously reported data from older kidneys.

Results Glomerular volume increased 4.6-fold from 0.13 ± 0.07 μm³ x 10⁶ in the pre-capillary loop stage, through 0.35 μm³ x 10⁶ at the capillary loop, to 0.60 μm³ x 10⁶ at the mature glomerular stage. Podocyte number per glomerulus increased from 326 ± 154 per glomerulus at the pre-capillary loop stage to 584 ± 131 per glomerulus at the capillary loop stage of glomerular development to reach a value of 589 ± 166 per glomerulus in mature glomeruli. Thus, the major podocyte number increase occurs in the early stages of glomerular development, in contradistinction to glomerular volume increase, which continues after birth in association with body growth.

Conclusions As glomeruli continue to enlarge, podocyte density (number per volume) rapidly decreases, requiring a parallel rapid increase in podocyte size that allows podocyte foot processes to maintain complete coverage of the filtration surface area. Hypertrophic stresses on the glomerulus and podocyte during development and early rapid growth periods of life are therefore likely to play significant roles in determining how and when defects in podocyte structure and function due to genetic variants become clinically manifest. Therapeutic strategies aimed at minimizing mismatch between these factors may prove clinically useful.

Keywords Podocyte · Glomerular maturation · Glomerular volume · Podocyte density · Glomerulosclerosis

Introduction
Podocytes are highly differentiated post-mitotic neuron-like cells with a limited capacity for replacement [1–5]. The realization that glomerular failure can be initiated and driven in a podocyte-dependent manner by glomerular enlargement per se, in the absence of immune, inflammatory or other insults to the glomerulus, provides insight into potential mechanisms of the progression of glomerular diseases [6, 7]. This concept is further amplified by recent studies on glomerular aging in which progressively decreasing podocyte density (number per glomerular tuft volume) with age is associated with hypertrophic podocyte stress and mass podocyte detachment, glomerular tuft collapse, and focal global glomerulosclerosis [8]. All progressive glomerular diseases are associated with an increased rate of podocyte detachment [9]. Thus, all progressive glomerular diseases that have an impact on adults can be seen to be superimposed upon a steadily declining podocyte density with age, such that older people are more severely affected.
than younger people, whatever the underlying glomerular insult [8]. These concepts can help to explain the over-riding impact of older age as a dominant risk factor for both chronic kidney disease and end-stage kidney disease (ESKD) [10]. They also offer new approaches for monitoring progression and response to treatment in glomerular diseases [11].

At the other end of the age spectrum a different constellation of glomerular diseases predominates, particularly affecting children and young adults, in which podocyte depletion and dysfunction also play key roles [5]. In one report, 85% of steroid-resistant nephrotic syndrome (SRNS) cases by 3 months of age and 66% of cases with onset by 1 year could be explained by recessive mutations in one of four genes (NPHS1, NPHS2, LAMB2 or WT1) [12]. To date, more than 40 genes have been identified as causing glomerular phenotypes, with some genes expressed specifically by podocytes (e.g., NPHS1 and NPHS2), whereas others are quite widely expressed, but, for unexplained reasons, present with a glomerular phenotype [12].

A spectrum of glomerular phenotypes can be identified and linked to podocyte dysfunction [5]. These include diffuse mesangial sclerosis (DMS), representing failed glomerular development at the pre-capillary loop stage (e.g., PLCE1) [13, 14]; congenital nephrotic syndrome (CNS), representing failed glomerular development at the capillary loops stage caused by variants in podocyte-expressed genes required for foot process structure and function (e.g., NPHS1, NPHS2) [5, 12, 15, 16]; minimal change nephrotic syndrome (MCD) manifests by diffuse foot process effacement and podocyte dysfunction that particularly affects children in the first years of life and is steroid-sensitive (e.g., EMP2, MAGI2, TENC1, DLC1, CDK20, and ITSN1) [12, 17]; and focal and segmental glomerulosclerosis (FSGS), representing podocyte depletion and dysfunction with characteristic segmental scarring occurring after glomerular development is completed [5]. More than 40 gene variants have been shown to confer susceptibility to FSGS, including genes that are also associated with DMS, MCD, and CNS phenotypes [12]. In addition, defects in collagen IV α3, 4, and 5 (COL4A3, COL4A4, and COL4A5) genes traditionally causing the Alport syndrome complex are now recognized to also cause an FSGS phenotype associated with podocyte depletion [18–21], and ApoL1 gene variants prevalent in African-Americans are a major cause of FSGS phenotypes [22, 23]. These clinical syndromes do not have major immune or inflammatory components, suggesting that they too, may, in part, be related to hypertrophic processes active in the perinatal and active growth periods of life. FSGS associated with obesity, large body size, and acromegaly are also examples where FSGS development appears to be directly linked to growth [6]. This is important conceptually, because if the translation from genetic susceptibility to clinical phenotype is caused in part by hypertrophy-induced events, then therapeutic strategies could potentially be directed against hypertrophy and related factors that tend to amplify the mismatch between glomerular volume and podocyte mass.

To examine this question we performed podometric studies to map the changes experienced by podocytes during development and early life. The data show that large increases in glomerular volume mandate parallel changes in podocyte density and cell size, thereby imposing major hypertrophic demands that have to be accommodated if podocytes are to successfully navigate the early years of life. These hypertrophic forces likely play a role in determining how genetic susceptibilities are transduced into clinical phenotypes and how fast they drive progression toward ESKD.

**Materials and methods**

**Validation of the cohort**

To ensure that the characteristics of the cohort were comparable with normal ranges, the body weight at birth was compared with normal reported ranges for fetal development [24] and post-natal growth was compared with average body weight for boys and girls using weight-for-age charts available through the National Center for Health Statistics [25]. For calculation of the normal post-conceptional weight range from these tables, we assumed that normal gestation length was 280 days [26].

**Podometric methodology**

The method used was as previously reported [27, 28]. In brief, formalin-fixed kidney tissues from autopsy were sectioned from paraffin blocks at 3 μm. Podocytes were identified if they expressed both GLEPP1, a podocyte-specific protein tyrosine phosphatase, and TLE4, a transcription factor expressed robustly by podocyte nuclei and co-localizing with WT1, as previously described [27, 28]. TLE4 immunofluorescence with triple amplification was performed for podocyte nuclei and GLEPP1 immuno-peroxidase staining was performed for podocyte cytoplasm, as previously described [27, 28]. Imaging of immunofluorescence was performed by photographing glomeruli in the red, green, and blue channels and creating composite images in which red fluorescence represented TLE4 and green fluorescence represented nonspecific fluorescence to allow structures that fluoresced nonspecifically to be recognized and eliminated from consideration. Composite images including blue DAPI staining were used to identify nuclei so that in each composite image all red TLE4-containing structures could be confirmed to be nuclei.

Podometric parameters were calculated by using the previously elucidated quadratic equation [27] that employs:
Integration of perinatal and later age podometric data

Data from the current study were integrated with previously reported adult podometric data [8]. For this analysis 38-week post-conceptional age is defined as 0 days postnatal age. The postnatal age of patients with a conceptional age of less than 38 weeks was represented as a negative number.

Statistical methods

For descriptive purposes, the mean ± SD was used to show the distributions of continuous variables. A linear regression model was utilized to quantify the relationship between the continuous variables. ANOVA was used for comparisons among multiple groups using Bonferroni correction for multiple comparisons. The level of significance was accepted at $p < 0.05$.

Analyses were performed using SPSS software, version 21 (IBM, Armonk, NY, USA). One data set was excluded from analyses because the glomerular volume was more than twice that of any other sample (a statistical outlier). The patient had trisomy 21 with ovarian and pulmonary hypoplasia and esophageal atresia. Histological evaluation of the kidney tissue used had not been cut in a systematic way in relation to kidney structural orientation, we were not able to differentially evaluate superficial and deep glomeruli.

Results

Table 1 shows group demographic data from 24 autopsied children who died from a variety of causes at age <1 year without kidney disease being the proximate cause of death. Most (72%) were pre-term deliveries, defined as birth before 38 weeks’ gestation.

One concern with using autopsy samples for analysis is that the severity of illness culminating in death would itself disrupt normal kidney development so severely that podometric data measured in these samples would not be representative of the normal state. To address this question, we first analyzed the cohort to determine whether or not growth data distributed within expected norms for gestational and post-conceptional age. Figure 1a shows how body weight at birth was related to gestational age at birth for the cohort as a whole. The 10th and 90th centile ranges overlap with the observed cohort data, showing that the cohort had relatively normal intrauterine growth. Furthermore, there were no differences in intrauterine growth rate between those who died soon after birth and those who survived longer suggesting that those who died shortly after birth had grown relatively normally in utero. Figure 1b shows how body weight continued to increase after birth in relation to the normal 5th and 95th percentile ranges. Figure 1c shows how kidney weight was linearly related to post-conceptional age. Figure 1d shows a further analysis of the data shown in Fig. 1b. The 50th percentile averaged growth for boys and girls overlaps with the correlation line for the cohort as a whole, suggesting that average growth in the cohort might have approximated expected values. To further examine the effect of faster or slower growth, we compared a group whose weight gain was above the 50th percentile range (“faster growers”) and a group whose rate of weight gain was below the 50th percentile range (“slower growers”).

Table 2 compares body weight, kidney weight, glomerular volume, podocyte number per glomerulus, and podocyte density between these two groups to determine whether growth rate differences of the degree observed would significantly affect podometric parameters. The “faster grower” group had significantly higher body weight ($p = 0.04$) and kidney weight ($p = 0.02$); however, none of the podometric parameters were significantly different in the “faster” and “slower” growing
groups. We therefore conclude that whether or not delivery occurred prematurely (before 38 weeks), or death occurred earlier or later, or weight gain for age was above or below the 50th percentile, the relationships of podometric parameters with post-conceptional age represented a continuum that was not impacted in a major way by the inter-current illness causing death. Therefore, podometric data from the cohort could reasonably be interpreted as being representative of early human life.

One case in the original cohort was identified where the glomerular volume was more than twice that of any other case. This case was a statistical outlier (>2 standard deviations above the mean) and associated with both ovarian and pulmonary hypoplasia and possible renal hypoplasia with small kidneys at autopsy. This case was excluded from the cohort used for further analysis as outlined in the Materials and methods.

In humans, nephrogenesis begins by 9 weeks and is thought to be completed between 32 and 36 weeks’ gestation.
Glomerular development was divided into groups defined as “immature” (pre-capillary loop stage) and mature (post-capillary loop and mature stage), as shown in Fig. 2.

The proportion of glomeruli at “immature” stage development in relation to post-conceptional age is also shown in Fig. 2. By a post-conceptional age of 38 weeks <10% of glomeruli were at “immature” stage development. The proportion of immature glomeruli at any point in time is therefore related to post-conceptional age, whether inside or outside the uterus.

To understand the time course of podometric changes with development we divided glomeruli into three groups. These included “immature” (pre-capillary loop), “mature (post-capillary loop) at less than 38 weeks’ gestation (<38 weeks)”, and “mature (post-capillary loop) at 38 weeks or greater of gestation (≥38 weeks)” (Fig. 3). The podometric methodology used requires the glomerular structure to be approximately spherical to estimate podocyte parameters; thus, the earliest stages of glomerular development, which are nonspherical, were not evaluated.

As shown in Table 3 and Fig. 4, glomerular volume increased 2.7-fold from the “immature” stage to the

| Slower growers | Faster growers | p value |
|----------------|----------------|---------|
| n = 8 | n = 6 | |
| Body weight at birth (g) | 2,666 ± 840 | 2,515 ± 1,089 | 0.78 |
| Body weight at autopsy (g) | 3,820 ± 1,328 | 6,201 ± 2,545 | 0.04 |
| Kidney weight (g) | 34.5 ± 7.5 | 61.5 ± 24.9 | 0.02 |
| Glomerular volume \( \times 10^6 \) \( \mu m^3 \) | 0.60 ± 0.20 | 0.50 ± 0.36 | 0.36 |
| Podocytes per glomerulus \( (n) \) | 613 ± 188 | 521 ± 105 | 0.30 |
| Podocyte density \( \text{per} \ 10^6 \ \text{\( \mu m^3 \)} \) | 1,054 ± 217 | 1,169 ± 344 | 0.46 |

Fig. 2 Relationship of glomerular maturity to gestational age. Upper panel: GLEPP1 immuno-peroxidase was used to map the stages of glomerular development. All pre-capillary loop stage glomeruli were designated as “immature” development. All capillary loop stage and mature glomeruli were designated as “mature” development. Lower panel: the relationship of stage of development (as defined in the text) to gestational age. By 38 weeks’ gestation <10% of glomeruli were scored as at an “immature” stage of development.

Table 2 Comparison of faster growers with slower growers

| Glomerular Volume \( \times 10^6 \) \( \mu m^3 \) | 2.7-fold increase from immature stage to mature stage. |
“mature stage at <38 weeks” and 4.6-fold from the “immature stage” to the “mature stage at ≥38 weeks” gestation. Podocyte nuclear number per glomerulus increased from 326 ± 154 in the “immature stage” glomeruli to 584 ± 131 in the “mature stage at <38 weeks” glomeruli, but did not further increase significantly between “mature stage development at <38 weeks” and “mature stage at ≥38 weeks” (589 ± 166 podocytes per glomerulus). Therefore, by the capillary loop stage of glomerular development, glomeruli had acquired their full complement of podocytes, although podocytes remained small and tightly packed at high density into small glomeruli. As development proceeded, podocyte density decreased in association with glomerular enlargement, such that the (estimated) podocyte volume was required to increase approximately 1.8-fold between the “immature stage” and the “mature stage at <38 weeks” and 2.6-fold by the “mature stage at ≥38 weeks”. Individual data points for this analysis are also shown in Fig. 4. These data emphasize the large changes in podocyte density and estimated cell volume that occur over the perinatal period in humans.

To put these perinatal podometric data into context, Fig. 5 compares the “mature stage” glomeruli at both <38 weeks and ≥38 weeks with glomeruli at other phases of life, using previously reported data [8]. During the perinatal period and over the first 12 years of life glomerular volume can be seen to increase about 5-fold, whereas podocyte number per glomerulus begins the steady decline that will continue over the life of the kidney. These changes mandate a large reduction in podocyte density over time that in turn requires the podocyte to increase its volume, estimated to be approximately 7-fold by 12 years and 17-fold by 72 years of age.

Discussion
To maintain the normal filtration barrier, the podocyte must completely cover the filtration surface area with foot processes. At the same time, our data show that the podocyte nuclear number per glomerulus does not increase after the capillary loop stage of glomerular development, in spite of continued glomerular enlargement that rapidly occurs in the perinatal and postnatal periods, and at a lesser rate throughout life. Some reports have suggested that podocyte replacement may occur from the parietal and/or juxta-glomerular compartments [31–36]. However, the quantitative capacity of these replacement pathways and the time period during development and post-natal life at which they may occur remain poorly defined, and quantitative studies suggest that their capacity for podocyte replacement might be small [37]. Significantly, podocytes are therefore required to cope with the demands of an increasing filtration surface area by hypertrophy. We previously modelled this process and demonstrated that failure of the podocyte per se to cope with hypertrophic stress
Thus, podocyte hypertrophic stress in its own right can be a driver of progression to ESKD [6, 7].

Podocyte cell structure is complex, consisting of a cell body and major and intermediate processes that serve as a platform for tertiary (actin-based) foot process attachment to the underlying basement membrane, allowing interdigitating foot processes between neighboring cells to form specialized intercellular junctions (slit diaphragms) through which the glomerular filtrate is formed. Foot processes use an integrin-based protein complex to attach and deliver key components to the underlying glomerular basement membrane (GBM) and thereby to communicate with endothelial and mesangial cells [38, 39]. Maintaining these critical foot process inter-relationships under hypertrophying conditions, particularly when rapidly occurring over short periods of time, must impose remarkable logistical challenges in space and time that have to be accommodated by as yet poorly understood signaling mechanisms.

With realization of the major developmental and hypertrophic stresses faced by the podocyte in the perinatal period, this cell is anticipated to be especially susceptible to genetic defects that might compromise its adaptive capacities. On the one hand, these include defects in specialized proteins uniquely expressed by podocytes and required for this cell to develop and perform its specialized functions, including forming and maintaining foot processes and slit diaphragms essential for filtration (e.g., \(NPHS1\) [nephrin] and \(NPHS2\) [podocin]) [15, 16] and delivery of the specialized type IV collagen alpha 3, 4, and 5 chains required to maintain the underlying mature GBM structure [38]. On the other hand, genetic variants in proteins common to many cell types are also associated with a proteinuria and nephrotic syndrome phenotype. Examples include signaling, sensing and coordinating proteins (e.g., \(PLCE1, TRPC6, ARHGAP24,\) and \(ARHGDA\)), cytoskeletal proteins (e.g., alpha actinin 4), adhesion proteins by which podocyte foot processes attach to the underlying basement membrane (e.g., \(ITGA3, ITGA4,\) and \(LAMB2\)) and co-enzyme Q pathway synthesis proteins necessary to protect the huge lipid surface area of the podocyte from mitochondria-induced oxidant damage [12, 22, 40]. In other words, the hypertrophic and signaling stresses experienced at particular times during podocyte development may demand an optimized functional capacity for some molecular pathways that are less critical in other cell types, thereby potentially explaining why variants in these rather widely expressed proteins cause a proteinuria and nephrotic syndrome phenotype at particular ages and stages of glomerular development.

The methodology used for our study provides only an approximate estimation of podocyte volume because the complexity of the foot process structure is not fully taken into account by the peroxidase immuno-histochemical staining approach. Nevertheless, approximations can be conceptually useful. In this report, we estimate that in mature glomeruli of the developing kidney (<38 weeks’ gestation to >38 weeks of gestation), the average podocyte volume increases at a very rapid rate. By 13 years of age (adolescence) the rate of podocyte enlargement remains high, but is at only one third the perinatal rate. During adult life between 20 and 72 years of age podocytes are still increasing in volume, but at a much slower rate (about 10% of the perinatal rate). However, over a

### Table 3 Podometric values for stages of glomerular development

|                        | Immature stage | Mature stage <38 weeks | Mature stage ≥38 weeks |
|------------------------|----------------|------------------------|------------------------|
| Glomerular volume (μm\(^3\) x 10\(^6\)) | 0.13 ± 0.07  (0.03–0.24) | 0.35 ± 0.08  (0.26–0.50) | 0.60 ± 0.19  (0.28–0.90) |
| Podocyte number per glomerulus | 326 ± 154  (71–549) | 584 ± 131  (406–850) | 589 ± 166  (393–1048) |
| Podocyte density (per 10\(^6\) μm\(^3\)) | 2,702 ± 451  (1,731–3,649) | 1,870 ± 250  (1,375–2,253) | 1,166 ± 310  (696–1732) |
| Total podocyte volume (x10\(^5\) μm\(^3\)) | 41.5 ± 23.4  (8.2–80.8) | 136.0 ± 45.3  (86.8–260.0) | 195.1 ± 81.7  (64.1–320.8) |
| Average podocyte volume (μm\(^3\)) | 131 ± 36  (76–215) | 233 ± 64  (143–397) | 335 ± 136  (122–583) |

“Immature stage” of development is at the pre-capillary loop stage. “Mature <38 weeks” includes all glomeruli at the capillary loop and later stages of development in kidneys before 38 weeks’ gestation. “Mature stage ≥38 weeks” includes all glomeruli at the capillary loop and later stages of development in kidneys at ≥38 weeks’ gestation. Values are mean ± SD with the range shown in parentheses. Total podocyte volume is the GLEPP1-positive area multiplied by the glomerular volume to give an estimate for the average volume of all podocytes present in glomeruli.
life-time this slower rate is associated with hypertrophic stress events associated with the development of global glomerulosclerosis [8].

A concern with the current study is that although body growth rates were quite well maintained up until time of death in the cohort examined, the kidney samples came from autopsies of patients who had died rather than being derived from biopsies obtained under normal physiological conditions. The events preceding death would likely have had an impact on the development of the kidney and other organs to some extent. Sutherland and colleagues demonstrated accelerated postnatal renal maturation following preterm birth by matching preterm infants and post-conceptional age-matched control infants who died suddenly in utero [41]. Furthermore, in a baboon model of preterm birth, Gubhaju and colleagues reported a marked increase in kidney size relative to control kidneys in the first 3 weeks after birth, in spite of no increase in body weight [42]. They suggested that this could represent a compensatory response to the increased functional demands placed on the preterm kidney as a result of separation from the
maternal milieu. Mechanisms leading to accelerated renal maturation observed in the preterm kidney are not well understood, but may also include factors that promote organ maturation, such as exposure to glucocorticoids, which are commonly administered before preterm delivery to aid postnatal respiratory function. Similar events would have occurred in our study sample. Therefore, although we document relatively normal growth occurring in the cohort used, interpretation of the data provided in this report must recognize these caveats, which could have an impact on the detailed data, but will probably not change the overall conclusions.

The methodology used in this study has been validated by comparisons with other methods, including ultrastructural methods [27, 28]. However, as noted above, podocyte structure is highly complex, so that immuno-peroxidase at the light microscopic level cannot provide a complete picture of actual podocyte cell volume. Nevertheless, this histological approach is reproducible, usable in archival paraffin-embedded tissues available from autopsy and biopsy series, and provides an approximation of the changes in cell size occurring over time. Puelles and colleagues, using a different morphometric method, reported autopsied kidney values from 4 children (aged 0.25 to 3 years) and 12 adults (aged 25 to 49 years) [43]. They reported that glomeruli from 25- to 49-year-olds contained statistically more podocytes (558 per glomerulus) than children (452 per glomerulus), although the glomeruli from children were smaller and therefore their podocyte density was higher than in adult glomeruli, as we also observed. The values obtained, including podocyte number per glomerulus, were within the range of those observed in the current study, although our data showed that podocyte number per glomerulus reached a maximum plateau by the capillary loop stage of development and did not appear to increase thereafter. Crobe and colleagues reported that podocyte number decreased about 40% (from 1,908 to 1,126 per glomerulus) from fetus to full term [44]. The estimated number of podocytes per
glomerulus in the Crobe report was 2- to 3-fold higher than our estimate and that of Puelles and colleagues [43]. These differences could well reflect the methodologies used, where podocytes in the Crobe report were identified at the light microscopic level without specific markers.

A further limitation of this study is that we focused on podocyte parameters, when in reality the glomerulus is a dynamic complex of interacting cell types (endothelial, mesangial, parietal epithelial, juxta-glomerular cells, and podocytes) and structures (GBM, mesangial matrix, Bowman’s capsule) perfused by pulsatile blood flow at high pressures. The observed podocyte density decrease during development occurs in association with complex events restructuring the glomerulus. These include, but are not limited to, the formation of new basement membrane, including switching collagen IV chains from α1 and α2 trimers to α3, 4, and 5 trimers made and secreted by podocytes into the GBM [37], extension and in-folding of capillary loops that increase the filtration surface area, increased blood space, and flow within capillary loops [38], formation of the mesangium and mesangial matrix, and accumulation of other glomerular cells, including endothelial, mesangial, juxta-glomerular, and parietal epithelial cells. Each of these processes requires specialized molecular machinery and regulation by signaling within and between cells. However, in spite of this complexity, there is now strong support for the concept that:

1. Podocyte depletion itself drives progression to ESKD
2. All genetic causes of glomerular phenotypes so far identified are in proteins expressed by podocytes
3. Progression in all glomerular diseases so far examined is associated with podocyte depletion [11]

Progress in science is often made by simplifying complex problems to make them accessible to the scientific method. The availability of specific markers that allows quantitation of podocyte parameters offers tools that can be used to reach into the glomerulus to dissect events [11]. Therefore, a focus on podocytes as a step toward trying to understand the biological complexities involved in glomerular diseases associated with early life is not unreasonable, although it should be kept firmly in mind that all changes observed in podocyte parameters will have their counterparts in other glomerular cell types and structures that together describe the complexity of glomerular diseases.

In summary, while underlying genetic “causes” of the nephrotic syndrome of childhood diseases are being identified in an increasing proportion of cases [45], the precise mechanisms by which these genetic variants become transduced into clinical syndromes remains largely undefined. The biology of the developing and growing glomerulus must be part of the explanation that links the underlying genetic susceptibilities and environmental factors (e.g., growth rate and weight gain) that combine to drive podocyte stress, leading to glomerular dysfunction and progressive glomerulosclerosis in a particular case. Understanding these stresses will provide insight into mechanisms and potentially offer strategies for mitigating the mismatch between hypertrophic demands and the podocyte’s capacity to comply.

Acknowledgements This work was supported in part by a Pilot and Feasibility Study grant from the Nephrotic Syndrome Study Network Consortium (NEPTUNE), U54-DK-083912, a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through a collaboration between the Office of Rare Diseases Research (ORDR), NCATS, and the National Institute of Diabetes, Digestive, and Kidney Diseases. Additional funding and/or programmatic support for this project has also been provided by the University of Michigan, the NephCure Kidney International Foundation and the Halpin Foundation. RW is supported by NIDDK of the National Institutes of Health (grants DK RO1 46073) and the University of Michigan O’Brien Kidney Core Center P30 DK081943.

Compliance with ethical standards Use of archival autopsy kidney tissues was approved by the University of Michigan Institutional Review Board (HUM00055525, HUM00083116).

Conflict of interest We have no potential conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Kriz W, Gretz N, Lemley KV (1998) Progression of glomerular diseases: Is the podocyte the culprit? Kidney Int 56:687–697
2. Kim YH, Goyal M, Kumit D, Wharram B, Wiggins J, Holzman L, Kershaw D, Wiggins R (2001) Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 60:957–968
3. Wharram BL, Goyal M, Gillespie PJ, Wiggins JE, Kershaw DB, Holzman LB, Dysko RC, Saunders TL, Samuelson LC, Wiggins RC (2005) Podocyte depletion causes glomerulosclerosis: Diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 16:2941–2952
4. Kriz W, LeHir M (2005) Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int 67:404–419
5. Wiggins RC (2007) The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 71:1205–1214
6. Fukuda A, Chowdhury MA, Venkatesaraddi MP, Wang SQ, Nishizono R, Suzuki T, Wickman LT, Wiggins JE, Muchayi T, Fingar D, Shelden KA, Inoki K, Wiggins RC (2012) Growth-dependent podocyte failure causes glomerulosclerosis. J Am Soc Nephrol 23:1351–1363
7. Kriz W (2012) Glomerular diseases: podocyte hypertrophy mismatch and glomerular disease. Nat Rev Nephrol 8:618–619
8. Hodgin JB, Bitzer M, Wickman L, Afshinnia F, Wang SQ, O’Connor C, Yang Y, Meadowbrooke C, Chowdhury M, Kikuchi M, Wiggins JE, Wiggins RC (2015) Glomerular aging and focal...
global glomerulosclerosis: a podometric perspective. J Am Soc Nephrol 26:3162–3178

9. Wickman L, Afshinnia F, Yang Y, Wang SQ, Fang F, Chowdhury M, Graham D, Hawkins J, Nishizono R, Tanzer M, Escobar GA, Rovin B, Song P, Gipson D, Kershaw D, Wiggins RC (2013) Urine podocyte mRNAs, proteinuria and progression in human glomerular diseases. J Am Soc Nephrol 24:2081–2095

10. Naik AS, Afshinnia F, Cibrik D, Hodglin JB, Wu F, Zhang M, Kikuchi M, Wickman L, Wang SQ, Afshinnia F, Yang Y, Wang F, Chowdhury M, Kershaw D, Wiggins RC (2015) Quantitative podocyte parameters predict human native kidney and allograft half-lives. JCI Insight 1(7):e6948

11. Kikuchi M, Wickman L, Hodglin JB, Wiggins RC (2015) Podometrics as a potential clinical tool for glomerular disease management. Semin Nephrol 35:245–255

12. Lovric S, Asaphr S, Tan W, Hildebrandt F (2016) Genetic testing in steroid-resistant nephrotic syndrome: when and how. Nephrol Dial Transplant 31:1802–1813

13. Hinkes B, Wiggins RC, Gbadegesin R, Vlangos CN, Seelow D, Nürnberg G, Garg P, Verma R, Chaib H, Hoskins BE, Asaphr S, Becker C, Hennes SC, Goyal M, Wharram BL, Schachter AD, Mudumana S, Drummond I, Kerjaschki D, Waldherr R, Dietrich A, Ozaltin F, Bakkaloglu A, Cleper R, Basel-Vanagaite L, Pohl M, Griebel M, Tsygin AN, Soylu A, Muller D, Sesti G, Bunney TD, Katan M, Liu J, Attanasio M, Otto EA, Akin R, Kasper J, Kelley GG, Smrcka A V, Gudermann T, Holzmann LB, Nürnberg P, Hildebrandt F (2006) Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 38:1397–1405

14. Gbadegesin R, Hinkes BG, Hoskins BE, Vlangos CN, Heringer SF, Liu J, Loinar C, Ozaltin F, Hashmi S, Utman R, Cleper R, Ettenger R, Antignac C, Wiggins RC, Zenker M, Kirchhoff F (2008) Mutations in PLCE1 are a major cause of isolated diffuse mesangial sclerosis (IDMS). Nephrol Dial Transplant 23:1291–1297

15. Tryggvason K (1999) Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 10:2440–2445

16. Tory K, Menyhárd DK, Woerner S, Nevo F, Gibbouval O, Kerti A, Sträinzer P, Arondel C, Huynh Cong E, Tulassay T, Mollet G, Percez J, Antignac C (2014) Mutation-dependent recessive inheritance of NPHS2-associated steroid-resistant nephrotic syndrome. Nat Genet 46:299–304

17. Asaphr S, Rao J, Lawson J, Tan W, Widmeier E, Lovric S, Warkeko J, Braun D, Gee HY, Jairpuri M, Zenker M, Hildebrandt F (2016) Recreessive mutations in 5 novel genes of interacting partners elucidate steroid sensitivity in nephrotic syndrome. J Am Soc Nephrol 27:158A (abstract)

18. Malone A, Phelan P, Hall G, Cetincelik U, Homstad A, Alonso A, Jiang R, Lindsey T, Wu G, Sparks M, Smith S, Webb N, Kalra P, Adeyemo A, Shaw A, Conlon P, Jennette J, Howell D, Winn M, Gbadegesin R (2014) Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis. Kidney Int 86:1259–1269

19. Venkat-Raman G, Ennis S (2015) Collagen (COL4) mutations – a single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. PLoS One 11:e0155255

20. Delatas C, Savva I, Voskarides K, Papazachariou I, Pierides A (2015) Carriers of autosomal recessive Alport Syndrome with thin GBM nephropathy presenting as focal segmental glomerulosclerosis in later life. Nephron 130:271–280

21. Wickman L, Hodglin JB, Wang SQ, Afshinnia F, Kershaw D, Wiggins RC (2016) Podocyte depletion in thin GBM and Alport syndrome. PLoS One 11:e0155255

22. Pollak MR (2014) Familial FSGS. Adv Chronic Kidney Dis 21:422–425

23. Kopp JB, Winkler CA, Zhao X, Radeva MK, Gassman JJ, D’Agati VD, Nast CC, Wei C, Reiser J, Guay-Woodford LM, Pollak MR, Hildebrandt F, Moxey-Mims M, Gipson DS, Trachtman H, Friedman AL, Kaskel FJ (2015) FSGS-CT study consortium. J Am Soc Nephrol 26:1443–1448

24. http://www.baby2see.com/medical/charts.html. Accessed 14 September 2016

25. National Center for Health Statistics at the Center of Disease Control and Prevention (CDC). www.cdc.gov/nchs/. Accessed on 29 October 2016

26. www.betterheath.vic.gov.au/health/healthliving/baby-due-date. Accessed 26 October 2016

27. Venkatreddy M, Wang SQ, Yang Y, Patel S, Wickman L, Nishizono R, Chowdhury M, Hodglin J, Wiggins PA, Wiggins RC (2014) Estimating podocyte number and density using a single histologic section. J Am Soc Nephrol 25:1118–1129

28. Yang Y, Hodglin JB, Afshinnia F, Wang SQ, Wickman L, Chowdhury M, Nishizono R, Kikuchi M, Huang Y, Samaniego M, Wiggins RC (2015) The two kidney to one kidney transition and transplant glomerulopathy: a podocyte perspective. J Am Soc Nephrol 26:1450–1465

29. Weibel ER, Gomez DM (1962) A principle for counting tissue structures on random sections. J Appl Physiol 17:343–348

30. Hinchliffe SA, Sargent PH, Howard CV, Chan YF, van Velzen D (1991) Human intrauterine renal growth expressed in absolute number of glomeruli assessed by the disector method and Cavalieri principle. Lab Invest 64:777–784

31. Appel D, Kershaw DB, Smeets B, Yuan G, Fuss A, Frye B, Elger M, Kriz W, Fioeje J, Moeller MJ (2009) Recruitment of podocytes from glomerular parietal epithelial cells. J Am Soc Nephrol 20:333–343

32. Lasagni L, Angelotti ML, Ronconi E, Lombardi D, Nardi S, Peired A, Becherucci F, Mazzinghi B, Sisti A, Romoli S, Burger A, Schaefer B, Buccoliero A, Lazzeri E, Romagnani P (2015) Podocyte regeneration driven by renal progenitors determines glomerular disease remission and can be pharmacologically enhanced. Stem Cell Reports 5:248–263

33. Eng DG, Sunseri MW, Kaverina NV, Roeder SS, Pippin JW, Shankland SJ (2015) Glomerular parietal epithelial cells contribute to adult podocyte regeneration in experimental focal segmental glomerulosclerosis. Kidney Int 88:999–1012

34. Kuppe C, Grone HJ, Ostendorf T, van Kuppevelt TH, Boor P, Floege J, Smeets B, Moeller MJ (2015) Common histological patterns in glomerular epithelial cells in secondary focal segmental glomerulosclerosis. Kidney Int 88:990–998

35. Kopp JB (2015) Replenishment of the podocyte compartment by parietal epithelial cells. Kidney Int 88:934–935

36. Kaverina NV, Eng DG, Schneider RR, Pippin JW, Shankland SJ (2016) Partial podocyte replenishment in experimental FSGS derives from non-podocyte sources. Am J Physiol Renal Physiol 310:F1397–F1413

37. Wanner N, Hartleben B, Herbach N, Goedel M, Stielke N, Zeiser R, Walz G, Moeller MJ, Gubler F, Huber TB (2014) Unraveling the role of podocyte turnover in glomerular aging and injury. J Am Soc Nephrol 25:707–716

38. Abrahamson DR (2012) Role of the podocyte (and glomerular endothelium) in building the GBM. Semin Nephrol 32:1443–1450

39. Bartlett CS, Jeansson M, Quaggin SE (2016) Vascular growth factors and glomerular disease. Annu Rev Plant Physiol Plant Mol Biol 77:437–461

40. Sadowski CE, Lovric S, Asaphr S, Pahst WL, Gey HY, Kohl S, Englmann S, Vega-Warner V, Fang H, Halbritter J, Somes MJ, Tan W, Shril S, Fessi I, Litton RP, Bockenhauer D, El-Desoky S, Kari JA, Zenker M, Kemper MJ, Mueller D, Fathy HM, Soliman NA, SRNS Study Group, Hildebrandt F (2015) A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol 26:1279–1289
41. Sutherland MR, Gubhaju L, Moore L, Kent AL, Dahlstrom JE, Horne RS, Hoy WE, Bertram JF, Black MJ (2011) Accelerated maturation and abnormal morphology in the preterm neonatal kidney. J Am Soc Nephrol 22:1365–1374
42. Gubhaju L, Sutherland MR, Yoder BA, Zulli A, Bertram JF, Black MJ (2009) Is nephrogenesis affected by preterm birth? Studies in a non-human primate model. Am J Physiol Renal Physiol 297:F1668–F1677
43. Puelles VG, Douglas-Denton RN, Cullen-McEwen LA, Li J, Hughson MD, Hoy WE, Kerr PG, Bertram JF (2015) Podocyte number in children and adults: associations with glomerular size and numbers of other glomerular resident cells. J Am Soc Nephrol 26:2277–2288
44. Crobe A, Desogus M, Sanna A, Fraschini M, Gerosa C, Fanni D, Fanos V, Van Eyken P, Faa G (2014) Decreasing podocyte number during human kidney intrauterine development. Am J Physiol Renal Physiol 307:F1033–F1040
45. Vivante A, Hildebrandt F (2016) Exploring the genetic basis of early-onset chronic kidney disease. Nat Rev Nephrol 12:133–146